Research programme: antibody therapeutics - Numab/Intarcia

Drug Profile

Research programme: antibody therapeutics - Numab/Intarcia

Alternative Names: Autoimmune disorders therapeutics - Numab/Intarcia; Diabetes therapeutics - Numab/Intarcia; ND 003; ND 007; Obesity therapeutics - Numab/Intarcia

Latest Information Update: 28 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Numab
  • Developer Intarcia Therapeutics; Numab
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action CD3 antigen inhibitors; Interleukin 5 receptor antagonists; Th17 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Asthma; Autoimmune disorders; Diabetes mellitus; Inflammation; Obesity

Most Recent Events

  • 16 Apr 2015 Early research in Autoimmune disorders in Switzerland (unspecified route)
  • 19 Mar 2015 Early research in Diabetes mellitus in Switzerland (unspecified route)
  • 19 Mar 2015 Early research in Obesity in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top